FDA approves pretomanid to treat tuberculosis patients in combination with bedaquiline and linezolid
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Today, the U.SFDA(http://announced the approval of pretomanid, developed by the non-profit global TBdrug(http://Development Alliance (TB Alliance), to treat specific highly drug-resistant tuberculosis (TB) patients in conjunction with bedaquiline and linealidzoDue to increasing bacterial resistance, multidrug-resistant TB and extensively drug-resistant TB have become a major threat to theofhealth(http:// in humansMost patients with widely drug-resistant TB may now need treatment with up to eight antibiotics up to 18 months or moreAccording to WHO estimates, the success rate for treatment of mDR TB patients is about 34%About Pretomanid
Pretomanid is a new chemical entityIts efficacy in combination with the combination therapy of bedaquinone and linazole was demonstrated in a critical clinical trial (http:// called Nix-TB The 109 patients who participated in the trial included people with widespread drug resistance TB and multiple drug resistance who were intolerant or unresponsive to pre-existing therapies The results showed that after six months of treatment, the success rate of this combination therapy was 89%, significantly higher than the historical success rate of treating patients with extensively drug-resistant TB
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
